treprostinil IV
Selected indexed studies
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (J Am Coll Cardiol, 2010) [PMID:20430262]
- Treprostinil sodium Pharmacia. (Curr Opin Investig Drugs, 2002) [PMID:12090728]
- Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension. (Am J Health Syst Pharm, 2021) [PMID:34100906]
_Worker-drafted node — pending editorial review._
Connections
treprostinil IV is a side effect of
Sources
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. (2010) pubmed
- Treprostinil sodium Pharmacia. (2002) pubmed
- Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension. (2021) pubmed
- Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. (2013) pubmed
- Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure. (2017) pubmed
- [Systemic sclerosis]. (2008) pubmed
- Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. (2006) pubmed
- Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. (2007) pubmed
- Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. (2019) pubmed
- Real-world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting. (2022) pubmed